biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD
Revolution Medicines
Revolution Medicines is a biotech organization headquartered in Redwood City, USA. It trades on NYSE under ticker RVMD. Primary therapeutic focus areas include Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Non-Small C
Company details
- Status
- Public
- HQ
- 700 Saginaw Dr., Redwood City, California 94063, US
- Founded
- 2014
- Employees
- 1,050
- Programs
- 26
- Drugs
- 28
- Patents
- 36
Quick answer
Revolution Medicines is a biotech organization headquartered in Redwood City, USA. It trades on NYSE under ticker RVMD. Primary therapeutic focus areas include Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Cancer (NSCLC), Solid Tumors, Pancreatic Cancer. NovaPharmaNews links 26 clinical program(s), 0 drug profile(s), and 36 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (10), phase 2 (10), phase 3 (6).
Company snapshot
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagn
- 26 active pipeline program(s) linked via ClinicalTrials.gov.
- 36 US patent(s) indexed to this assignee profile.
- 26 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Revolution Medicines. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
ASCO 2026 Preview: Key Data and Trends in Cancer Research
- trial_data
Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
- trial_data
Revolution Medicine Pancreatic Cancer: Demand Surge Strains Daraxonrasib Access
- trial_data
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Recent coverage
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Daraxonrasib nearly doubled overall survival in a Phase III trial for pancreatic ductal adenocarcinoma, an unprecedented outcome. This article analyzes the clinical data, regulatory implications, and strategic impact for pharma BD and investors.
Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
Revolution Medicines’ daraxonrasib nearly doubled median survival in a Phase 3 trial for pancreatic cancer, offering a new standard of care. This article analyzes the clinical data, side effect profile, and competitive implications for pharma teams.
Revolution Medicine Pancreatic Cancer: Demand Surge Strains Daraxonrasib Access
Revolution Medicines' daraxonrasib has shown a dramatic overall survival benefit in pancreatic cancer, but patient demand is overwhelming the expanded access program. For pharma strategists, the supply-demand imbalance signals potential launch revenue upside and commercial execution risk.
ASCO 2026 Preview: Key Data and Trends in Cancer Research
This ASCO preview highlights crucial developments in cancer research, focusing on key data presentations and emerging trends that will shape the oncology landscape. Investors and BD teams should monitor these advancements for strategic insights.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Revolution Medicines.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Revolution Medicines.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Revolution Medicines?
-
Is Revolution Medicines publicly traded?
-
What drugs does Revolution Medicines develop or market?
-
What are the latest developments for Revolution Medicines?
-
What therapeutic areas does Revolution Medicines focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.